Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Completed

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133

Clinical Study of Chimeric CD(Cluster of Differentiation)133 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Malignancies

NCT02541370↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome
Finished, no results posted
Phase
Phase 1 / Phase 2
Status
Completed
Study type
Interventional
Start
June 2015
Ended
June 2019
Enrollment
20 participants
Sites
1
Primary outcomes
Occurrence of study related adverse events
Sponsor type
Academic / other
Results posted
No
Last update
17 December 2019

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells. PURPOSE: This clinical trial is studying genetically engineered lymphocyte therapy in treating patients with Relapsed and/or Chemotherapy Refractory Advanced Malignancies.

Detailed description public domain (ClinicalTrials.gov)

I. Determine the safety and feasibility of the chimeric antigen receptor T cells transduced with the anti-CD133 (cluster of differentiation antigen 133 ) vector (referred to as CART-133 cells). II. Determine duration of in vivo survival of CART-133 cells. RT-PCR (reverse transcription polymerase chain reaction) analysis of whole blood will be used to detect and quantify survival of CART-133 TCR (T-cell receptor) zeta:CD137 and TCR zeta cells over time. SECONDARY OBJECTIVES: I. For patients with detectable disease, measure anti-tumor response due to CART-133 cell infusions. II. To determine if the CD137 transgene is superior to the TCR zeta only transgene as measured by the relative engraftment levels of CART-133 TCR zeta:CD137 and TCR zeta cells over time. III. Estimate relative trafficking of CART-133 cells to tumor in bone marrow and lymph nodes. IV. For patients with stored or accessible tumor cells determine tumor cell killing by CART-133 cells in vitro. V. Determine if cellular or humoral host immunity develops against the murine anti-CD133, and assess correlation with loss of detectable CART-133 (loss of engraftment). VI. Determine the relative subsets of CART-133 T cells (Tcm, Tem, and Treg).

Papers 2